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Abstract
Background: Actinobacillus pleuropneumoniae is the etiological agent of porcine pleuropneumonia, which leads to
large economic losses to the swine industry worldwide. In this study, S-8△clpP△apxIIC, a double-deletion mutant of
A. pleuropneumoniae was constructed, and its safety and protective efficacy were evaluated in pigs.
Results: The S-8△clpP△apxIIC mutant exhibited attenuated virulence in a murine (BALB/c) model, and caused no
detrimental effects on pigs even at a dose of up to 1.0 × 109 CFU. Furthermore, the S-8△clpP△apxIIC mutant was
able to induce a strong immune response in pigs, which included high levels of IgG1 and IgG2, stimulated gamma
interferon (IFN-γ), interleukin 12 (IL-12), and interleukin 4 (IL-4) production, and conferred effective protection
against the lethal challenge with A. pleuropneumoniae serovars 7 or 5a. The pigs in the S-8△clpP△apxIIC immunized
groups have no lesions and reduced bacterial loads in the lung tissue after challenge.
Conclusions: The data obtained in this study suggest that the S-8△clpP△apxIIC mutant can serve as a highly
immunogenic and potential live attenuated vaccine candidate against A. pleuropneumoniae infection.
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Background
Actinobacillus pleuropneumoniae is a highly adapted
pathogen that causes porcine pleuropneumonia, which is
an extremely contagious respiratory disease [1]. The dis-
ease is often fatal and characterized by fibrinous,
hemorrhagic, and necrotic lung lesions, which remains
an important global problem in the swine industry [2].
Transmission of the pathogen occurs through an aerosol
route during close contact with diseased pigs or asymp-
tomatic carriers, and it can infect pigs of different ages
[3]. The clinical features can span from peracute disease
with quick death to chronic infection leading to reduced
growth rates, and the pigs frequently become asymp-
tomatic carriers. To date, 16 serovars of A. pleuropneu-
moniae have been identified and all serovars can cause
disease [4, 5]. Although the incidence of outbreaks has
reduced in the developed countries, A. pleuropneumo-
niae remains one of the main causes of economic loss to
the global swine production, especially in developing
countries [6].
Antimicrobial therapy has been used to prevent and
control porcine pleuropneumonia, but it results in the
growing problems of multidrug-resistance and antibiotic
residues in pigs [7–9]. Concern was raised that
multidrug-resistance could be transmitted between dif-
ferent pathogens in pigs followed through the food chain
to produce a risk to human health. Thus, vaccination be-
comes the most effective method of preventing A. pleur-
opneumoniae infection. It has been found that pigs
surviving natural infection were protected against hom-
ologous and heterologous serovar infection [10]. It is
speculated that live bacteria can induce in vivo expres-
sion of protective antigens and confer cross-protection.
Thus, the application of an attenuated live vaccine is an
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ideal approach for vaccination against diversified sero-
vars of A. pleuropneumoniae [11, 12].
ClpP protease is a family of ATP-dependent protease,
which plays a key role in the degradation of misfolded
proteins and the stress tolerance in bacteria [13]. The
role of ClpP as an important virulence factor has been
demonstrated in several pathogenic bacteria [14, 15]. A
previous study of Salmonella typhimurium and Salmon-
ella enteritidis also showed that the virulence of clpP de-
letion mutants were remarkably decreased and that
these mutants can serve as live oral vaccine candidates
[16]. In our previously study, the clpP-deleted mutant of
A. pleuropneumoniae serovar 7, a prevalent serovar in
China, was constructed and its physiological features
were analyzed. The ClpP protease mediates A. pleurop-
neumoniae tolerance to multiple environmental
stressors, affects the biofilm formation, and may play a
critical role in the virulence regulation [17]. The ApxII
toxin is the most important virulence factor in A. pleur-
opneumoniae serovar 7, and is encoded by the apxIICA
gene cluster. The apxIIA gene encodes the ApxIIA toxin
structural protein, and the apxIIC gene encodes the
post-translational activating protein that is essential for
the ApxII toxin activation, thus disruption in the apxIIC
gene of A. pleuropneumoniae results in secretion of the
inactive ApxII toxin but with full antigenicity [18].
In the present study, we constructed the double-
deletion mutant S-8△clpP△apxIIC of A. pleuropneumo-
niae and evaluated the feasibility of its use as a live
attenuated negative marker vaccine based on the viru-
lence, changes in clinical symptoms, immune responses,
and protective effects in pigs against challenge with the




One hundred and ten 6-week-old female BALB/c mice
(Beijing Vital River Laboratory Animal Co., Ltd.) were
used in the study, with identical feeding conditions. A
total of 45 piglets were obtained for use in this study
from a farm that was free from A. pleuropneumoniae
and other respiratory pathogens including Streptococcus
suis, Haemophilus parasuis, and porcine reproductive
and respiratory syndrome virus (PCR-negative for nasal
and tonsillar swabs and serological-negative in corre-
sponding ELISA assays). The 45 piglets were randomly
divided into nine groups of same number and were
separately fed with same feeding conditions. The animal
experiment in this study was approved by the Animal
Ethics Committee of Harbin Veterinary Research
Institute of the Chinese Academy of Agricultural
Sciences (CAAS) and carried out in strict accordance
with animal ethics guidelines and approved protocols.
Bacterial strains and growth conditions
A. pleuropneumoniae strains S-8 (serovar 7), Shope 4074
(serovar 1), K17 (serovar 5a), the S-8△clpP mutant and
the S-8△clpP△apxIIC mutant were grown at 37 °C in
tryptic soy broth (TSB) or tryptic soy agar (TSA) (Becton
Dickinson, Franklin Lakes, NJ, USA) containing nicotina-
mide dinucleotide (NAD, 10 μg/mL; Sigma-Aldrich).
Chromosomal inactivation of the apxIIC gene of S-8△clpP
Primers IICLF/IICLR, and IICRF/IICRR (Table 1) were
used to amplify the two segments flanking with the
apxIIC gene, IIC-L and IIC-R, as the recombination
homologous arms. Using single-overlap extension PCR
(SOE PCR), the fragment with a 270 bp internal deletion
in the apxIIC gene (from nt 18 to 297) was generated,
and cloned into the conjugative vector pEMOC2 [19] to
construct plasmid pEM△apxIIC. Using E. coli β2155 and
a single-step transconjugation system [20, 21], plasmid
pEM△apxIIC was applied to introduce the apxIIC muta-
tion into the S-8△clpP mutant. After two homologous
recombination steps, the A. pleuropneumoniae S-
8△clpP△apxIIC mutant strain was verified by PCR and
sequencing using IICJDF/IICJDR primers.
Growth experiment and hemolytic assay
A. pleuropneumoniae wild-type strain S-8, the S-8△clpP
mutant, and the S-8△clpP△apxIIC mutant were routinely
grown in 3 ml of TSB for 16 h, then diluted to OD600 of
0.1. The fresh cultures were then inoculated in 30 ml of
TSB and grown at 37 °C. The OD600 values were re-
corded at an interval of 1 h using the Eppendorf
BioPhotometer (Eppendorf, Germany).
A. pleuropneumoniae wild-type strain S-8, the S-8△clpP
mutant, and the S-8△clpP△apxIIC mutant were respect-
ively inoculated onto TSA plates supplemented with 5%
defibrinated sheep erythrocytes, and incubated at 37 °C
for 18 h. The hemolysis activity was assessed by visualizing
clear zones around the colony.
Virulence studies in mice
To determine the residual virulence of the S-8△clpP△ap-
xIIC mutant, various concentrations of A. pleuropneumo-
niae strains S-8 and S-8△clpP△apxIIC mutant were
injected intraperitoneally into mice. One hundred and ten
6-week-old female BALB/c mice (Beijing Vital River La-
boratory Animal Co., Ltd.) were randomly divided into
eleven experimental groups (n = 10). Five experimental
groups were inoculated with 100 μL of PBS containing the
S-8△clpP△apxIIC mutant (1.0 × 108 to 1.0 × 1010 CFU/
mouse, Table 2). As a positive control, five experimental
groups were inoculated with the wild-type strain S-8
(1.0 × 105 to 1.0 × 107 CFU/mouse, Table 2) using the
identical method. Non-infected mice in the control
group were inoculated with 100 μL of sterile PBS.
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After infection, mice were monitored twice daily for a 14-
day period and humanely euthanized if moribund [22].
The 50% lethal dose (LD50) values of S-8 and S-
8△clpP△apxIIC were calculated by Karber’s method [23].
Virulence studies in pigs
Twenty-five 8-week-old pigs were randomly assigned into
five experimental groups (n = 5). The pigs in group 1 were
inoculated with 1 × 107 CFU of S-8△clpP△apxIIC via an in-
tranasal (i.n.) route. The pigs in group 2 were injected with
1 × 107 CFU of S-8 via the i.n. route. The pigs in group 3
were injected with 1 × 109 CFU of S-8△clpP△apxIIC via
the i.n. route. The pigs in group 4 were injected with
1 × 109 CFU of S-8 via the i.n. route. The pigs in group
5, the control group, were inoculated with an equivalent
amount of PBS via the i.n. route. The rectal temperature,
appetite, respiratory rate, and lethargywere recorded daily
for 14 days after inoculation as described previously [24].
Pigs that showed severe respiratory distress during the ob-
servation period were euthanized. All of surviving pigs were
euthanized at day 14 post-challenge, and the lung lesions
were examined and scored as described previously [25].
Briefly, the lung lesion was determined by divided the
complete lung into seven lobes, each lobe was scored 1-5
by assessing the pneumonic area.
Table 2 Virulence of S-8△clpP△apxIIC and the wild-type strain









S-8 1.0 × 107 10/10 5.62 × 105 1
3.16 × 106 9/10
1.0 × 106 6/10
3.16 × 105 5/10
1.0 × 105 0/10
S-8△clpP△apxIIC 1.0 × 1010 10/10 1.12 × 109 1995
3.16 × 109 8/10
1.0 × 109 5/10
3.16 × 108 1/10
1.0 × 108 0/10
Control PBS broth 0/10 - -
a Groups of ten BALB/c mice were given intraperitoneal injections of 100 μL of
bacterial suspension containing various quantities of A. pleuropneumoniae
strains. Survival was recorded for 14 days after infection
b LD50 was calculated by the Karber’s method [23]
c Fold attenuation was normalized to wild-type strain S-8
Table 1 Characteristics of bacterial strains, plasmids, and primers used in this study
Strains, plasmids, and primers Characteristics or sequence Source or reference
Strains
E. coli β2155 thrB1004 pro thi strA hsdS lacZ△M15 (F’ lacZ△M15 laclqtraD36 proA+
proB+)△dap :: erm (Ermr))recA :: RPA-2-tet(Tcr)::Mu-km (Kmr) λpir
[21]
A.pleuropneumoniae S-8 A. pleuropneumoniae serotype 7 clinical isolate from the lung of a diseased
pig in northern China
[17]
A.pleuropneumoniae S-8△clpP Unmarked clpP gene knockout mutant of A. pleuropneumoniae S-8 [17]
A.pleuropneumoniae S-8△clpP△apxIIC Unmarked clpP/apxIIC genes knockout mutant of A. pleuropneumoniae S-8 This work
Plasmids
pEMOC2 Conjugative vector based on pBluescript SK with mob RP4, polycloning site,
Cmr, and transcriptional fusion of the omlA promoter with the sacB gene
Accession no. AJ868288
[19]
pEM△apxIIC Conjugative vector pEMOC2 with a 270 bp deletion in the apxIIC gene
which have a 1.4-kb upstream fragment and 1.4-kb downstream fragment
This work
Primers
IICLF 5’ GCGTCGACATGACAACACCAATGATTGATTTAC 3’, upstream primer with
internal SalI site (underlined)
This work
IICLR 5’ AATCCCCGAAAGCATCATCCCTCCCATTC 3’, downstream primer with
reverse complement sequence(underlined) of sequence in bold from
primer IICRF
This work
IICRF 5’ GGATGATGCTTTCGGGGATTCATCTCTATTG 3’, upstream primer with reverse
complement sequence(underlined) of sequence in bold from primer IICLR
This work
IICRR 5’ TTGCGGCCGCGTTGTAATAAGTCCCGTAACACCAG 3’, downstream primer
with internal NotI site (underlined)
This work
IICJDF 5’ GAAGAGCCATTACCCAACAAC 3’, upstream primer for identification of
apxIIC gene deletion
This work
IICJDR 5’ ATACAATAGAGATGAATCCCCG 3’, downstream primer for identification
of apxIIC gene deletion
This work
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Protection studies in pigs
Twenty 4-week-old pigs were randomly assigned into
four experimental groups (n = 5). The pigs in group 1
and group 3 were immunized via an intramuscular (i.m.)
route with 1 × 107 CFU of S-8△clpP△apxIIC in 1 mL of
PBS. The pigs in group 2 and group 4 were inoculated
with 1 mL of PBS. The booster immunization was per-
formed 21 days after the primary vaccination.
On day 14 following the booster immunization, the
pigs in groups 1 and group 2 were challenged with
5.0 × 109 CFU of A. pleuropneumoniae homologous
serovar 7 (S-8) via the i.n. route. The pigs in groups
3 and group 4 were challenged with 5.0 × 108 CFU of A.
pleuropneumoniae heterologous serovar 5a (K17) via the
i.n. route. After challenge, the pigs from each group were
observed daily for clinical symptoms for 14-day period
after challenge as previously described [24]. Pigs that
showed severe respiratory distress during the observation
period were euthanized. At day 14 post-challenge, all sur-
viving pigs were euthanized and lung lesions were exam-
ined and scored as mentioned above [25].
Antibody measurements
Serum samples were collected from pigs in different
groups before the first immunization (day 0), before the
booster immunization (day 21) and before homologous
or heterologous challenge (day 35). Antibodies against
ApxII were examined using indirect ELISA as previously
described [26]. 96-well plates were coated with 5 μg/mL
of ApxII in 50 mM sodium carbonate buffer (pH 9.6) at
4 °C overnight. The wells were washed three times with
PBST buffer (PBS supplemented with 0.05% Tween-20)
and then blocked with PBS containing 5% bovine serum
albumin at 37 °C for 1 h. Serum samples diluted in PBS
were then added to the wells and incubated for 1 h at
37 °C. After the plates were washed, horseradish perox-
idase (HRP)-conjugated goat anti-porcine IgG was di-
luted and added to the plates and incubated for 1 h at
37 °C. For determining the IgG isotypes, the sera were
added to the S-8△clpP△apxIIC-coated plates and incu-
bated with mouse anti-pig IgG1 Monoclonal Antibody
(Clone K139 3C8, Thermo, United Kingdom) or mouse
anti-pig IgG2 Monoclonal Antibody (Clone K68 Ig2,
Thermo, United Kingdom), followed by HRP-conjugated
goat anti-mouse IgG (Abcam, United Kingdom). After
three washes, the substrate solution tetramethylbenzidine
(TMB) and H2O2 were added to the wells and incubated
for 15 min, and the reaction was stopped by the addition of
2 M sulfuric acid. The absorbance was measured at 450 nm
using an ELISA reader. Each sample was tested in triplicate.
Determination of cytokines by ELISA
Serum samples at day 0, day 21, and day 35 were ana-
lyzed for swine gamma interferon (IFN-γ), interleukin 12
(IL-12) (R&D Systems, USA), and interleukin 4 (IL-4)
(Invitrogen, USA) using ELISA kits performed according
to the manufacturer’s instructions. Concentrations of
swine IFN-γ, IL-12, and IL-4 in tested sera samples were
determined by extrapolation to the linear portion of the
standard curve, which was generated with supplied refer-
ence standards.
Bacterial loads analysis
Pigs from each group were necropsied immediately after
euthanasia and lung tissues were aseptically collected.
Samples were weighed, suspended in 1 mL PBS, and ho-
mogenized using a tissue homogenizer. The tissue ho-
mogenates were serially diluted with sterile PBS. Viable
counts in serial dilutions of homogenates were deter-
mined following culture on TSA plates for 18 h at 37 °C.
Identification of A. pleuropneumoniae was conducted by
colony PCR assay and expressed as log10 CFU/g.
Statistical analysis
All statistical analyses were conducted using GraphPad
Prism version 5.01 (GraphPad Software Inc., USA). Stu-
dent’s t-test was used to evaluate the significance of the
differences between multiple experimental groups. The
data were expressed as the mean +/- standard deviation
and values of P < 0.05 were considered to be significant.
Results
Construction of the S-8△clpP△apxIIC mutant strain
To construct the double-deletion mutant S-8△clpP△ap-
xIIC, we deleted the apxIIC gene of A. pleuropneumo-
niae S-8△clpP mutant via the allelic exchange of the
wild-type apxIIC gene with an unmarked, in-frame dele-
tion lacking 270 bp of the apxIIC ORF (Fig. 1a and
Fig. 1b). To test the stability of the in-frame deleted
apxIIC gene in the genome of the A. pleuropneumoniae
S-8△clpP△apxIIC mutant, a PCR assay was performed
on the genomes of the mutant from 10 passages to de-
tect a 294-bp DNA fragment characteristic of the in-
frame deleted apxIIC. This fragment was observed in all
10 consecutive passages (Fig. 1c), suggesting a stable in-
frame deletion in the S-8△clpP△apxIIC genome.
The growth curves of the S-8△clpP mutant, the S-
8△clpP△apxIIC mutant, and the wild-type strain S-8
were similar at 37 °C (Fig. 2a). The hemolytic assay was
examined in the wild-type strain S-8, the S-8△clpP mu-
tant, and the S-8△clpP△apxIIC mutant. S-8 and the S-
8△clpP mutant with the integrated apxII operon had
hemolytic activity, as shown by clear zones around the
colonies (Fig. 2b). However, the clear zones were absent
in the S-8△clpP△apxIIC mutant, the result of deletion of
the apxIIC gene rendered it unable to activate ApxII
toxin, and thus lacking hemolytic activity.
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Virulence of the S-8△clpP and S-8△clpP△apxIIC mutants in
mice
The attenuation of virulence was investigated by deter-
mining the LD50 values of the S-8△clpP△apxIIC mutant,
and the wild-type strain S-8 in BALB/c mice. The data
showed LD50 values of 5.62 × 10
5 CFU per mouse for the
wild-type strain S-8, and 1.12 × 109 CFU per mouse for
the S-8△clpP△apxIIC mutant. Compared to the wild-
type strain S-8, the S-8△clpP△apxIIC mutant was atten-
uated by approximately 1195-fold in mice. LD50 values
showed that the S-8△clpP△apxIIC mutant was highly
attenuated.
Virulence of the S-8△clpP△apxIIC mutant in pigs
The results of the safety study on the S-8△clpP△apxIIC
mutant in pigs are listed in Table 3. Two of five pigs
Fig. 1 Characterization of the A. pleuropneumoniae mutant S-8△clp△apxIIC. a Schematic representation of the A. pleuropneumoniae apxIIC locus.
Binding locations for the primers IICLF/IICLR and IICRF/IICRR used to amplify the two flanking regions (1412 bp and 1443 bp, respectively) of the apxIIC
gene were shown in the schematic, and primers IICJDF/IICJDR were used to identify the S-8△clp△apxIIC mutant (294 bp) and S-8△clp mutant (564 bp).
The shadowed domain represents a 270 bp in-frame deletion in the apxIIC gene, hp indicates the encoding gene of the hypothetical protein. b PCR
identification of the S-8△clp△apxIIC mutant using the primers IICJDF/IICJDR. For lane 3, the identified S-8△clp△apxIIC mutant (294 bp); for other lanes,
the single crossover mutant (564 bp and 294 bp). c PCR identification of the 10 passages of the S-8△clp△apxIIC mutant. For lanes 1–10, 10 successive
passages of the S-8△clp△apxIIC mutant; for lane M, DL2000 DNA molecular marker (from top to bottom: 2000, 1000, 750, 500, 250, and 100 bp)
Fig. 2 Growth characteristics and hemolytic activities of the A. pleuropneumoniae mutants. a The growth curves of the S-8, S-8△clp and
S-8△clp△apxIIC strains. Overnight cultures were inoculated into fresh TSB and then incubated at 37 °C. Growth was monitored by OD600 at an
interval of 1 h. b Hemolytic activity test for the S-8, S-8△clp and S-8△clp△apxIIC strains. Section 1, S-8; section 2, S-8△clp; section 3, S-8△clp△apxIIC
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inoculated with 1.0 × 109 CFU of the S-8△clpP△apxIIC
mutant via the i.n. route showed a slight increase in rec-
tal temperatures (40.1 °C < body temperatures < 40.3 °C)
after 8–20 h post-infection and exhibited only mild
clinical symptoms of porcine pleuropneumonia, such as
decreased appetite. However, all of these pigs recovered
quickly in 24 h and were in good health afterward. All
of the five pigs inoculated with 1.0 × 107 CFU of the S-
8△clpP△apxIIC via the i.n. route exhibited no clinical
signs of porcine pleuropneumonia. Compared to the
groups inoculated with the S-8△clpP△apxIIC mutant,
the groups inoculated with the S-8 strain exhibited
more severe clinical symptoms of porcine pleuropneu-
monia. Three of five pigs which were inoculated with
1.0 × 109 CFU of S-8 were euthanized because of severe
clinical symptoms. The lesions in their lungs were
severe with massive hemorrhages and fibrinous
inflammation was observed. Compared to serious lung
lesions of pigs in the S-8-inoculated groups, there are
no or few lung lesions in the pigs of the S-8△clpP△ap-
xIIC-inoculated groups (Fig. 3). The average lung lesion
scores were 16.2 for 1.0 × 107 CFU and 21.8 for 1.0 ×
109 CFU of S-8 challenge. However, the groups inocu-
lated with S-8△clpP△apxIIC showed significantly lower
lung lesion scores, with 1.8 and 3.0 following challenge
with 1.0 × 107 CFU or 1.0 × 109 CFU, respectively
(Table 3).
Immune response of pigs to the S-8△clpP△apxIIC mutant
Serum samples from pigs of each group were obtained
from blood via anterior vena cava venipuncture.
Figure 4a showed a significant increase in antibody titers
in pigs immunized with S-8△clpP△apxIIC on days 21
and 35, however, no antibody was detected in the PBS
control groups. The IgG isotype was determined to
check the specific antibody types against S-8△clpP△ap-
xIIC. The levels of isotypes IgG1 and IgG2 in the
immunized groups were significantly higher (P < 0.01)
than that of PBS control groups (Fig. 4b, c).
Levels of IFN-γ in sera from S-8△clpP△apxIIC
immunization groups were significantly higher than
those of PBS control groups on days 21 and 35 (P < 0.01)
(Fig. 5a). Levels of IL-12 in the S-8△clpP△apxIIC
immunization groups were also significantly higher
than those of control groups during the observation
period (P < 0.01) (Fig. 5b). Both the IFN-γ and IL-12
concentrations in sera from S-8△clpP△apxIIC immu-
nized animals increased substantially on day 21 and ex-
hibited a smaller increase on day 35. While the IL-4
concentrations in sera from S-8△clpP△apxIIC immu-
nized groups exhibited an approximately equal increase
on day 21 and day 35, higher than in sera from the PBS
control groups (P < 0.01) (Fig. 5c).
Protective efficacy in pigs
The protective efficacy of the S-8△clpP△apxIIC mutant
against lethal challenge with A. pleuropneumoniae sero-
var 7 S-8 or serovar 5a K17 in pigs was evaluated in
terms of body temperature, clinical signs, lung lesions,
and survival rate. The results are summarized in Fig. 6
and Table 4. Pigs in the S-8△clpP△apxIIC-immunized
groups showed slight or no lethargy, anorexia or dyspnea
after challenge with A. pleuropneumoniae serovar 5a or
serovar 7. Four immunized pigs had a transient in-
creased body temperature (<40.3 °C) on day 0 upon
challenge with A. pleuropneumoniae S-8 or K17 but re-
covered afterward. During the 14-day observation
period, all immunized pigs survived with clinical symp-
toms ranging from none to only mild. All of the pigs in
the PBS control groups developed anorexia, increased
respiratory rate, and depression after challenge with A.
pleuropneumoniae S-8 or K17. The average body
temperature increased (41.2 °C) for at least 3 days. Four
of ten pigs showed severe respiratory distress within
Table 3 Virulence of the A. pleuropneumoniae S-8△clpP△apxIIC mutant in pigs
Group Strain for challenge Challenge dosea (CFU) Temperature (°C) b Appetitec Lethargyc Dyspneac Lung lesion score d
1 S-8△clpP△apxIIC 1.0 × 107 39.2 ± 0.3 0.2 ± 0.4* 0.1 ± 0.2** 0.2 ± 0.2** 1.8 ± 3.0**
2 S-8 1.0 × 107 40.1 ± 0.4 1.8 ± 1.3 1.7 ± 0.7 1.9 ± 0.7 16.2 ± 8.5
3 S-8△clpP△apxIIC 1.0 × 109 39.4 ± 0.5 0.4 ± 0.5* 0.3 ± 0.3** 0.4 ± 0.4** 3.0 ± 2.2**
4 S-8 1.0 × 109 40.2 ± 0.6 2.4 ± 1.6 2.2 ± 0.6 2.5 ± 0.5 21.8 ± 5.8
5 PBS 0 39.4 ± 0.3 0 0 0 0
a Groups of five pigs were given intranasal inoculations with 1 mL of bacterial suspension containing various quantities of A. pleuropneumoniae strains. Survival
was recorded for 14 days after infection
b The average temperature value for each piglet during the observation period was calculated and the mean temperature value for each group was determined
c Clinical signs were scored as described by Jolie et al [24]. Appetite was scored as follows: 0, did eat; and 1, did not eat. The total score equaled the number of
12-h periods of not eating over the 36-h observation period. Lethargy was scored as follows: 0, normal; 1, slight inactivity; 2, moderate; and 3, severe. Dyspnea
was scored as follows: 0, normal; 1, slight; 2, moderate; and 3, severe. The final scores were obtained from the average of all of the data within the observation
time and are expressed as arithmetic means ± SD; *, significance at a P value of <0.05; **, significance at a P value of <0.01
d The lung lesion score was determined as described by Hannan et al [25]
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48 h and were euthanized. Three pigs subsequently ex-
hibited severe respiratory distress during the next four
days and were euthanized. Only two pigs challenged
with S-8 and one pig challenged with K17 in the control
groups survived over the 14-day observation period.
At necropsy, the pigs in the PBS control groups
showed severe lung lesions and pleuritis. Hemorrhage
and fibrinous exudation on the lung and pleura were
found in these pigs. The average lung lesion scores were
20.2 and 22.8 for challenge with A. pleuropneumoniae
S-8 or K17, respectively. However, in comparison to
the PBS control groups, the S-8△clpP△apxIIC-immu-
nized groups showed significantly lower lung lesion
scores of 1.4 and 1.8 for challenge with A. pleurop-
neumoniae S-8 or K17, respectively.
Bacteriological analysis of tissue homogenates
Bacterial loads in lung homogenates were counted after
challenge with A. pleuropneumoniae S-8 or K17 (Fig. 7).
The numbers of CFUs recovered from the homogenized
Fig. 3 Pathological changes of the lungs of pigs infected with A. pleuropneumoniae. Groups of pigs were inoculated with different doses of S-8
and S-8△clp△apxIIC. At 14 days post-infection, all pigs were euthanized and lungs were collected and subjected to pathological examination
Fig. 4 Levels of IgG antibody (a), IgG1 (b), and IgG2 (c) in the sera of piglets. Blood samples were collected prior to and following immunization
on days 0, 21, and 35 from the S-8△clp△apxIIC immunized groups and PBS control groups, and the antibody responses were determined by
indirect ELISA. The results are expressed as the means ± SD
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lung tissues in S-8△clpP△apxIIC immunized groups were
significantly lower (P < 0.01) than those of PBS control
groups.
Discussion
With the growing emergence of drug resistance and the
problem of antibiotic residues, vaccination becomes the
most effective method of preventing A. pleuropneumo-
niae infection [7, 11]. Previous studies found that pigs
surviving natural infection of A. pleuropneumoniae
could be fully protected against homologous strain and
partially against heterologous serovars, suggesting that
live bacteria likely induced in vivo expression of
protective antigens and conferred cross-protection [11].
Thus, an attenuated live vaccine is widely acknowledged
as an ideal approach for vaccination against porcine
pleuropneumonia.
The ideal live vaccine of porcine pleuropneumonia
should be low virulent and cause minimum lung lesions
[11]. Our previous study constructed S-8△clpP, an A.
pleuropneumoniae clpP gene deletion mutant, and illus-
trated the important function of the ClpP protease in
the stress response and biofilm formation of A. pleurop-
neumoniae, suggesting a putative role for ClpP protease
in the virulence regulation [17]. Afterwards, the viru-
lence of S-8△clpP was determined using the BALB/c
mouse infection model. The finding that the S-8△clpP
moderately attenuated by approximately 71-fold (data not
shown) was unexpected as a previous study had found
that clpP deletion strains of S. typhimurium and S. enteri-
tidis were attenuated by approximately 10,000-fold [16].
Thus, in this study, we further deleted the apxIIC gene
that encodes the ApxII activating protein, and rendered
the double-deletion mutant S-8△clpP△apxIIC secreting
unactivated ApxII toxins but with complete antigenicity
[18]. Compared to the wild-type strain, S-8△clpP△apxIIC
was greatly attenuated by approximately 1195-fold. We
next evaluated the virulence of S-8△clpP△apxIIC in pigs
via intranasal inoculation, with the results showing that
pigs inoculated with 1.0 × 107 CFU of the S-8△clpP mu-
tant displayed no clinical signs of porcine pleuropneumo-
nia but exhibited only transient depression when
inoculated with 1.0 × 109 CFU. Moreover, there are no or
little lung lesions in the pigs of the S-8△clpP△apxIIC-inoc-
ulated group, which showed that the S-8△clpP△apxIIC
mutant was adequately attenuated and has almost no det-
rimental effects on pigs that remained healthy throughout
the experiment.
An essential characteristic for an effective attenuated
live vaccine is that the strain should remain highly im-
munogenic [11]. Pigs vaccinated with the A. pleuropneu-
moniae S-8△clpP△apxIIC mutant exhibited a significantly
increased ApxII-specific IgG Ab response compared to
pigs injected with PBS. Interestingly, both A. pleuropneu-
moniae-specific IgG1 and IgG2 titers increased following
the first immunization and booster immunization. The
Fig. 5 Levels of IFN-γ, IL-12, and IL-4 in the sera of piglets. Blood samples were collected prior to and following immunization on days 0, 21, and
35 from the S-8△clp△apxIIC immunized groups and PBS control groups, and the levels of IFN-γ (a), IL-12 (b), and IL-4 (c) were determined by commercial
kit. The results are expressed as the means ± SD
Fig. 6 Survival of pigs following intranasal challenge with A. pleuropneumoniae strains S-8 or K17
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production of IgG isotypes in pig is elicited by type 1
(IFN-γ, IL-12) and type 2 (IL-4) cytokines, which lead
the responses to a cell-mediated or antibody-mediated
immune response [27]. In pigs, IgG2 is linked to the
production of IFN-γ and IL-12 and correlates with the
Th1 response [27, 28]. Conversely, the production of
the specific IgG1 antibody partially relies on the pres-
ence of the Th2 cytokine IL-4 [29]. In this study, we
also found that on day 35, the levels of IFN-γ, IL-12,
and IL-4 were significantly higher in sera from S-
8△clpP△apxIIC immunized pigs than those in sera from
PBS control groups, but IL-4 concentrations were lower
than IFN-γ and IL-12 concentrations in sera from the
immunization groups. These data suggested that
immunization with A. pleuropneumoniae S-8△clpP△ap-
xIIC generated a slight bias towards the Th1-type im-
mune response. However, the IgG1 titers and IL-4
concentrations in the S-8△clpP△apxIIC immunized pigs
were still much higher than those in the PBS control
groups. These data showed that the Th2-type immune
response also plays a partial role in immunization with
live A. pleuropneumoniae S-8△clpP△apxIIC. Unlike the
other A. pleuropneumoniae live attenuated mutant that
is significantly biased toward a Th1-type immune re-
sponse [30], S-8△clpP△apxIIC generated a more bal-
anced and broader immune response.
Cross-protection is a crucial characteristic that is im-
portant to achieve widespread use of a vaccine. Our
findings demonstrated that immunization with the S-
8△clpP△apxIIC mutant could induce acquired immunity
and confer a marked resistance against the lethal chal-
lenge with A. pleuropneumoniae virulent homologous
strain S-8 and heterologous serovar 5a. Although S-
8△clpP△apxIIC exhibited good immune protection as a
live vaccine, a few pigs after challenge still had few
pathological lesions. As it is unlikely that the multiple-
gene deleted mutant can revert back to the wild-type
genotype, we will further delete other important viru-
lence genes of A. pleuropneumoniae in our future stud-
ies and construct a multiple-gene deleted mutant as a
safe, attenuated live vaccine to prevent and control A.
pleuropneumoniae infection.
Conclusion
In conclusion, data presented in this study indicated that
the immunizations with the candidate vaccine S-
8△clpP△apxIIC were safe in pigs; and conferred efficient
protection against the homologous or heterologous sero-
var infection. Overall, the S-8△clpP△apxIIC mutant of A.
pleuropneumoniae has the potential as a novel live atten-
uated vaccine against porcine pleuropneumonia, al-
though further trials are needed.
Table 4 Protective efficacy of the S-8△clp△apxIIC mutant against A. pleuropneumoniae S-8 and K17 challenge in pigs
Group Immunogen Strain for challenge Temperature (°C) a Appetiteb Lethargyb Dyspneab Lung lesion scorec
1 S-8△clpP△apxIIC S-8 39.4 ± 0.2 0.2 ± 0.3* 0.2 ± 0.3** 0.1 ± 0.2** 1.4 ± 2.2*
2 PBS S-8 40.3 ± 0.5 2.4 ± 1.1 2.0 ± 0.6 2.3 ± 0.6 20.2 ± 11.9
3 S-8△clpP△apxIIC K17 39.6 ± 0.3 0.3 ± 0.4* 0.3 ± 0.4** 0.4 ± 0.4** 1.7 ± 2.5**
4 PBS K17 40.5 ± 0.4 2.6 ± 1.7 2.3 ± 0.5 2.6 ± 0.4 22.8 ± 9.3
a The average temperature value for each piglet during the observation period after challenge was calculated and the mean temperature value for each group
was determined
b Clinical signs were scored as described by Jolie et al [24]. Appetite was scored as follows: 0, did eat; and 1, did not eat. The total score equaled the number of
12-h periods of not eating over the 36-h observation period. Lethargy was scored as follows: 0, normal; 1, slight inactivity; 2, moderate; and 3, severe. Dyspnea
was scored as follows: 0, normal; 1, slight; 2, moderate; and 3, severe. The final scores were obtained from the average of all of the data within the observation
time and are expressed as arithmetic means ± SD; *, significance at a P value of <0.05; **, significance at a P value of <0.01
c The lung lesion score was determined as described by Hannan et al [25]
Fig. 7 Bacterial loads in lung homogenates after challenge with A. pleuropneumoniae strains S-8 or K17. The logarithm value (Log10) of the CFU in
each gram of tissue sample was recorded. The immunized groups were vaccinated with S-8△clp△apxIIC and the PBS control groups were injected
with PBS. The results are expressed as the means ± SD
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